Obstetrics & Gynecology:
Prostaglandin E2 Gel Versus Misoprostol for Cervical Ripening in Patients With Premature Rupture of Membranes After 34 Weeks
Frohn, W. Eric MD; Simmons, Stephanie MD; Carlan, S. J. MD
Department of Obstetrics and Gynecology, Arnold Palmer Hospital for Children and Women, Division of Orlando Regional Healthcare, Orlando, Florida.
Address reprint requests to: S. J. Carlan, MD, Department of Obstetrics and Gynecology, Orlando Regional Healthcare System, 105 West Miller Street, Orlando, FL 32806, E‐mail: email@example.com.
Received July 10, 2001. Received in revised form September 13, 2001. Accepted October 2, 2001.
OBJECTIVE: To compare intravaginal misoprostol to prostaglandin (PG) E2 for cervical ripening in women with premature rupture of the membranes (PROM) after 34 weeks of gestation.
METHODS: Women with PROM after 34 weeks of gestation and an unripe cervix were randomized to receive PGE2 (2.5 mg) or misoprostol (50 μg). Both agents were placed intravaginally immediately after randomization, and the dose was repeated 6 hours later if necessary. After another 6 hours from the second insertion, oxytocin treatment was started if labor had not begun. Forty patients in each group were required to show a 30% improvement in delivery within 12 hours in the misoprostol group.
RESULTS: One hundred nine patients were randomized; 54 were assigned to misoprostol and 55 to PGE2. Important demographic and clinical characteristics were similar between the groups. The mean time from first insertion to delivery was 16.4 hours in the misoprostol group and 22.0 hours in the PGE2 group. A second dose was required less frequently in the misoprostol group (22% vs 62% in the PGE2 group), and the percentage of patients delivered within 12 hours was higher in the misoprostol group (41% vs 16%). Tachysystole occurred in 20% and 6% of women in the misoprostol and PGE2 groups, respectively. Hyper‐stimulation occurred in 9% and 0%, and cesarean delivery in 19% and 26% of women in the misoprostol and PGE2 groups, respectively. Neonatal outcome was similar between groups.
CONCLUSION: Intravaginal misoprostol is more effective than local PGE2 application to treat PROM after 34 weeks of gestation, but tachysystole occurs more commonly with misoprostol.
Current obstetric management of preterm rupture of membranes (PROM) at term includes immediate delivery.1 Management of preterm PROM is controversial, but several studies suggest intentional delivery is a reasonable option after 30 weeks,2 34 weeks,3,4 or 32 weeks of gestation with mature amniotic fluid lung studies.5 Local application of prostaglandin (PG) E2 has been shown to be an effective method of cervical ripening in preterm6,7 and term patients with PROM.8–11 Misoprostol also has been shown to be effective compared with oxytocin in patients with PROM who are at or near term.12–15 However, misoprostol has not been compared with PGE2 in studies designed exclusively for women with PROM. We compared local application of PGE2 gel with intravaginal misoprostol in women with PROM at or after 34 weeks of gestation who had an unripe cervix and were undergoing intentional labor induction.
MATERIALS AND METHODS
All women with spontaneous rupture of membranes at or beyond 34 weeks gestation who attended the Arnold Palmer Hospital for Children and Women from January 1, 1995, through December 31, 2000, were considered candidates for this study. Approval was obtained from the Orlando Regional Healthcare System Investigational Review Board. Women who met study criteria were counseled and gave informed consent to participate. Ruptured membranes were diagnosed when amniotic fluid drained from the cervical os during sterile speculum examination or if a pool of fluid in the posterior fornix had a positive result to both fern and phenaphthazine (nitrazine tests). Inclusion criteria were singleton gestations; absence of nonreassuring fetal heart rate patterns; cephalic presentation; gestational age of at least 34 weeks, as determined by date of last menstrual period, serial prenatal examination, or prenatal ultrasono‐graphic examination; no evidence of labor, cervical dilatation less than 3 cm and effacement of no more than 80%, no contraindication to labor or vaginal delivery; and spontaneous rupture of membranes. Patients were excluded if they had estimated fetal weight over 4500 g; evidence of intrauterine infection; or any contraindication to use PG, such as severe cardiovascular disease, renal failure, glaucoma, or sickle cell disease. Patients with one previous low transverse cesarean delivery were not excluded.
Women were assigned to receive misoprostol or PGE2 gel by using a computer‐generated random number table. Group allocations were placed in consecutively numbered sealed opaque envelopes. The envelopes were generated in lots of 50 with equal numbers of assignments to PGE2 or misoprostol; all envelopes were used before the next lot was started. Women assigned to the misoprostol group received 50 μg (half of a 100‐μg tablet) of misoprostol (Cytotec; GD Searle and Company, Chicago, IL) intravaginally in the posterior fornix. The dose was repeated in 6 hours if the patient was not in labor (at least three contractions in 10 minutes, with cervical change.) The maximum total dose of misoprostol was 100 μg, or two doses. Women assigned to the PGE2 group received application of 2.5 mg of PGE2 gel in the vagina every 6 hours. The preparation and protocol for the PGE2 has been described elsewhere.16 If the patient was not in labor by 12 hours after the first dose of medication, an oxytocin induction was started.17
The initial determination of cervical dilatation and effacement was made by the obstetrics‐gynecology resident on admission. The fetal heart rate was monitored by using continuous electronic fetal monitoring in all participants. We reviewed each fetal heart rate monitoring strip after delivery to assess the frequency and duration of tachysystole and hyperstimulation. Tachysystole was defined as at least six contractions in 10 minutes for two consecutive 10‐minute periods. Hyperstimulation was defined as the presence of tachysystole associated with fetal tachycardia, late decelerations, or loss of beat‐to‐beat variability. Recognized episodes of hyperstimulation were managed with change in maternal position, oxygen administration, and 250 μg of terbutaline given subcutaneously. The occurrence of chorioamnionitis (maternal fever usually associated with maternal and fetal tachycardia, uterine tenderness, and peripheral leukocytosis) and postpartum endometritis (presence of maternal fever and uterine tenderness, leukocytosis, and foul‐smelling lochia) was evaluated in all patients. Sepsis in the neonate was defined as at least one positive blood culture believed not to be a contaminant. The physicians who managed labor were not blinded to study group allocation.
Power analysis was based on detection of a 30% improvement in delivery within 12 hours, from 35%10 to 65% in the misoprostol group. Assuming an α value of .05 and 80% power, 40 patients in each group were required. Characteristics and outcome variables were analyzed by using the Student t‐test, Mann Whitney U test, or χ2 analysis. P < .05 indicated statistical significance. Statistical and power analysis were performed by using computer software package SPSS (Chicago, IL). Statistical analysis was done on an intention‐to‐treat basis.
Fifty‐four of the 109 women enrolled were allocated to receive misoprostol, and 55 received PGE2 gel. The distribution of patient age, parity, gestational age, maternal weight, previous cesarean delivery, time from PROM to randomization, and proportion of patients with an unfavorable cervix were similar in the misoprostol and PGE2 groups (Table 1). Twenty‐four (44%) and 19 (35%) of patients in the misoprostol and PGE2 groups, respectively, were at more than 37 weeks of gestation (P = .29). Tachysystole during ripening occurred in 11 (20%) patients in the misoprostol and 3 (6%) in the PGE2 groups (P = .02, χ2 test). Hyperstimulation occurred in 5 (9%) women in the misoprostol and to women in the PGE2 group (P = .02, χ2 test).
Table 2 compares outcome variables and mode of delivery in the two study groups. None of the cesarean sections were performed during the ripening period for hyperstimulation. The mean time from start of induction to delivery was significantly shorter in the misoprostol group. A significantly lower maximum rate of oxytocin was administered to women in the misoprostol group. The indications for cesarean delivery were similar between the misoprostol and PGE2 groups; the most common reasons were nonreassuring fetal surveillance (5 [9%] patients vs with 6 [11%] patients, respectively; P = .53, χ2) and arrest of labor (4 [7%] patients vs 6 [11%] patients; P = .77, χ2). Table 3 shows the cumulative number of patients delivered from first insertion. Profiles of intrapartum complications and adverse maternal or perinatal outcomes were similar in both study groups (Table 4).
Intravaginal application of PGE2 and misoprostol for cervical ripening and labor induction in patients with PROM at and near term have been studied and found to be of benefit.10,14,15 Until now, misoprostol had not been tested against PGE2 in a study designed exclusively for patients with PROM. Several previous studies, however, included PROM patients. Intravaginal misoprostol at starting doses of 25 μg,18 50 μg,19,20 and 100 μg21 was compared with PGE2 in term pregnancies and was found in each study to be superior to PGE2. The percentage of patients with PROM in the studies varied from 1%18 to 36%.19 Our study also suggests that intravaginal misoprostol is superior to PGE2 in patients with PROM after 34 weeks of gestation.
Intentional delivery before term and without evidence of lung maturity in patients with PROM remains controversial. Recent data indicate that expectant management of patients with PROM after 34 weeks of gestation results in a significantly higher frequency of chorioamnionitis and neonatal sepsis.1,4,22 We observed an incidence of positive neonatal blood cultures of 9% in the misoprostol group and 7% in the PGE2. These rates are similar to those in the study of Mercer et al,5 who reported a confirmed neonatal sepsis incidence of 6.8% in women with PROM at 32–36 weeks of gestation who had immediate induction. They used oxytocin as the inducing agent, and the time from start to delivery was 14 hours compared with 16 hours in our study.
The incidence of tachysystole of 20% in our study probably reflects the intravaginal misoprostol dose of 50 μg. The dosing regimen of misoprostol was chosen on the basis of our experience16 with use of this medication for cervical ripening and labor induction. More recent investigations15 suggest that use of 25 μg of intravaginal misoprostol every 6 hours has a tachysystole rate of 6% and may be the optimal dose in patients with PROM. Although there is a trend toward longer hospitalizations in neonates of the misoprostol group, our numbers are insufficient to detect potentially important adverse events.
Bias may have been introduced because our study design did not require masking of the investigator. However, the use of randomization at study enrollment and strict study and labor and delivery protocols should have minimized selection or measurement bias.
When the study protocol was initially developed, PG application for cervical ripening in pregnant women with a previous low transverse cesarean delivery was thought to be safe.23 Current opinion now questions the safety of both PG24 and misoprostol25 use in pregnant women with a previous cesarean delivery.
In conclusion, in women with PROM after 34 weeks of gestation, intravaginal misoprostol shortened the time to delivery compared with PGE2 gel.
1. Mozurkewich EL, Wolf FM. Premature rupture of membranes at term: A meta-analysis of three management schemes. Obstet Gynecol 1997;89:1035–43.
2. Cox SM, Levino KJ. Intentional delivery versus expectant management with preterm ruptured membranes at 30 to 34 weeks gestation. Obstet Gynecol 1995;86:875–9.
3. Neerhof MG, Carvello C, Haney EI, Silver RK. Timing of labor induction after premature rupture of membranes between 32 and 36 weeks gestation. Am J Obstet Gynecol 1999;180:349–52.
4. Naef RW, Allbert JR, Ross EL, Weber M, Martin RW, Morrison JC. Premature rupture of membranes at 34 to 37 weeks gestation: Aggressive versus conservative management. Am J Obstet Gynecol 1998;178:126–30.
5. Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: A randomized trial. Am J Obstet Gynecol 1993;169:775–82.
6. Ekman-Ordeberg G, Uldbjerg N, Ulmsten U. Comparison of intravenous oxytocin and vaginal prostaglandin E2 gel in women with unripe cervixes and premature rupture of the membranes. Obstet Gynecol 1985;66:307–10.
7. Goeschen K. Premature rupture of membranes near term: Induction of labor within the cervical prostaglandin E2 gel or intravenous oxytocin. Am J Perinatol 1989;6:181–4.
8. Malik N, Gittens L, Gonzalez D, Bardeguez A, Ganesh V, Apuzzio J. Clinical amnionitis and endometritis in patients with premature rupture of membranes: Endocervical prostaglandin E2 gel versus oxytocin for induction of labor. Obstet Gynecol 1996;88:540–3.
9. Gonen R, Samberg I, Dejani S. Intracervical prostaglandin E2 for induction of labor in patients with preterm rupture of membranes and an unripe cervix. Am J Perinatol 1994; 11:436–8.
10. Ray DA, Gearity TJ. Prostaglandin E2 for induction of labor in patients with preterm rupture of membranes at term. Am J Obstet Gynecol 1992;166:836–43.
11. Mahmood TA, Dick MJW. A randomized trial of management of pre-labor rupture of membranes at term in nulliparous women using vaginal prostaglandin gel. Obstet Gynecol 1995;85:71–4.
12. Ngai SW, Chan YM, Lam SW, Lao TT. Labour characteristics in uterine activity: Misoprostol compared with oxytocin in women at term with pre-labor rupture of membranes. Br J Obstet Gynaecol 2000;107;222–7.
13. Butt KD, Bennett KA, Crane JMG, Hutchens D, Young DC. Randomized comparison of oral misoprostol and oxytocin for labor induction in term pre-labor membrane rupture. Obstet Gynecol 1999;94:994–9.
14. Sanchez-Ramos L, Chin AH, Kaunitz AM, Gaudier FL, Delke I. Labor induction with intravaginal misoprostol in term premature rupture of membranes: A randomized study. Obstet Gynecol 1997;89:909–12.
15. Wing DA, Paul RH. Induction of labor with misoprostol for premature rupture of membranes beyond thirty-six weeks' gestation. Am J Obstet Gynecol 1998;179:94–9.
16. Carlan SJ, Danna P, Durkee D, Quinsey C, Lanaris B. Randomized prospective study of preinduction cervical ripening with sequential use of intravaginal prostaglandin E2 gel. Obstet Gynecol 1995;85:608–13.
17. American College of Obstetricians and Gynecologists. Induction and augmentation of labor. ACOG technical bulletin no. 217 Washington DC: American College of Obstetricians and Gynecologists, 1995.
18. Blanchette HA, Nayak S, Erasmus. Comparison of the safety and efficacy of intravaginal misoprostol (prostaglandin E1) with those of dinoprostone (prostaglandin E2) for cervical ripening and induction of labor in a community hospital. Am J Obstet Gynecol 1999;180:1551–9.
19. Surbek DV, Boesiger H, Hoesli I, Pavic N, Holzgreve W. A double-blind comparison of the safety and efficacy of intravaginal misoprostol and prostaglandin E2 to induce labor. Am J Obstet Gynecol 1997;177:1018–23.
20. Sanchez-Ramos L, Peterson DE, Delke I, Gaudier FL, Kaunitz. Labor induction with prostaglandin E1 misoprostol compared with dinoprostone vaginal insert: A randomized trial. Obstet Gynecol 1998;91:401–5.
21. Nunes F, Rodrigues R, Meirinho M. Randomized comparison between intravaginal misoprostol and dinoprostone for cervical ripening and induction of labor. Am J Obstet Gynecol 1999;181:626–9.
22. Ladfords L, Tessin I, Mattsson LA, Eriksson M, Seeberg S, Fall O. Risk factors for neonatal sepsis in offspring of women with prelabor rupture of the membranes at 34–42 weeks. J Perinat Med 1998;26:94–101.
23. Blanco JD, Collins M, Willis D, Prien S. Prostaglandin E2 gel induction of patients with prior low transverse cesarean section. Am J Perinatol 1992;9:80–3.
24. Lyndon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. N Engl J Med 2001;345:3–8.
25. American College of Obstetricians and Gynecologists. Response to Searle's drug warning on misoprostol. ACOG committee opinion no. 248. Washington, DC: American College of Obstetricians and Gynecologists, 2000.
© 2002 The American College of Obstetricians and Gynecologists